Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
EV-209
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
- NCT07475806 ↗
- Recruiting
- Astellas Pharma Global Development, Inc.
- Deep
We haven't built an HCP commentary report on EV-209 (enfortumab vedotin and pembrolizumab in Muscle-invasive Bladder Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EV-209 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 15 | |
| Podcasts | 9 | |
| YouTube | 5 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin Plus Pembrolizumab for Bladder Preservation in Participants With Muscle-invasive Bladder Cancer (EV-209)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Muscle-invasive Bladder Cancer
- Interventions
- Enfortumab Vedotin; Pembrolizumab
- Arms
- Enfortumab Vedotin with Pembrolizumab · Experimental
- Enrollment
- 240 (estimated)
- Primary outcomes
- Overall clinical complete response (cCR) rate after treatment with enfortumab vedotin in combination with pembrolizumab as assessed by investigator
- Bladder-intact event-free survival (BI-EFS) rate in participants who achieve cRC after 9 cycles of treatment with enfortumab vedotin in combination with pembrolizumab as assessed by investigator
- Sponsor
- Astellas Pharma Global Development, Inc. with Pfizer
- Start
- Mar 12, 2026
- Primary completion
- Nov 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT07475806 · updated Oct 22, 2026